Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fonseca

Showing results (331-340 of 391) with videos related to

Pageof 40
Sort By:
Blood Cancer Journal|March 21, 2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantationV Roy, A K Stewart, P L Bergsagel, et al.
Frontiers in Cellular and Infection Microbiology|December 26, 2022
Prevalence of bat viruses associated with land-use change in the Atlantic Forest, BrazilElizabeth H Loh, Alessandra Nava, Kris A Murray, et al.
Annals of Hematology|March 7, 2015
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P)K M Kortüm, C Langer, J Monge, et al.
Leukemia|October 7, 2006
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaR Fonseca, S A Van Wier, W J Chng, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Leukemia|February 20, 2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialC B Reeder, D E Reece, V Kukreti, et al.
Leukemia|June 15, 2007
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolutionA K Stewart, H Chang, S Trudel, et al.
Molecular Pharmacology|June 2, 2018
Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II InhibitionCheng Chang, Kari R Fonseca, Cheryl Li, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Leukemia|February 20, 2003
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myelomaC S Debes-Marun, G W Dewald, S Bryant, et al.
Pageof 40

Showing results (331-340 of 391) with videos related to

Sort By:
Pageof 40
Blood Cancer Journal|March 21, 2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantationV Roy, A K Stewart, P L Bergsagel, et al.
Frontiers in Cellular and Infection Microbiology|December 26, 2022
Prevalence of bat viruses associated with land-use change in the Atlantic Forest, BrazilElizabeth H Loh, Alessandra Nava, Kris A Murray, et al.
Annals of Hematology|March 7, 2015
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P)K M Kortüm, C Langer, J Monge, et al.
Leukemia|October 7, 2006
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myelomaR Fonseca, S A Van Wier, W J Chng, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Leukemia|February 20, 2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialC B Reeder, D E Reece, V Kukreti, et al.
Leukemia|June 15, 2007
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolutionA K Stewart, H Chang, S Trudel, et al.
Molecular Pharmacology|June 2, 2018
Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II InhibitionCheng Chang, Kari R Fonseca, Cheryl Li, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
Leukemia|February 20, 2003
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myelomaC S Debes-Marun, G W Dewald, S Bryant, et al.
Pageof 40